country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-146358

Copy Link Print Information

Anticancer agent 49

Anticancer agent 49 (compound 69) is a broad spectrum anticancer agent. Anticancer agent 49 inhibits tubulin polymerization. Anticancer agent 49 shows antiproliferative activity. Anticancer agent 49 has the potential for the research of solid and hematological tumors.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 2395009-34-2
分子式: C₂₆H₂₅N₃O₄
分子量:443.49

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (271 KB)

Anticancer agent 49 構造式

CAS 番号: 2395009-34-2

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	41 nM Compound: 69	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
HT-29	IC₅₀	34 nM Compound: 69	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
KBM5	IC₅₀	10 nM Compound: 69	Cytotoxicity against human KBM5 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human KBM5 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
KBM5	IC₅₀	12 nM Compound: 69	Cytotoxicity against human KBM5 cells expressing IM-resistant Bcr/Abl T315I mutant assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human KBM5 cells expressing IM-resistant Bcr/Abl T315I mutant assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
KU812 cell line	IC₅₀	5 nM Compound: 69	Cytotoxicity against human KU812 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human KU812 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
MCF7	IC₅₀	15 nM Compound: 69	Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 31727471]
SW480	IC₅₀	153 nM Compound: 69	Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
SW-620	IC₅₀	61 nM Compound: 69	Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
T-24	IC₅₀	58 nM Compound: 69	Cytotoxicity against human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
T98G	IC₅₀	24 nM Compound: 69	Cytotoxicity against human T98G cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against human T98G cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 31727471]
U-87MG ATCC	IC₅₀	47.6 nM Compound: 69	Cytotoxicity against human U87MG cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against human U87MG cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 31727471]

体外実験

Anticancer agent 49 (compound 69) inhibits tubulin polymerization and MCF-7 cancer cell growth with IC₅₀s of 0.38 µM and 15 nM, respectively^[1].
Anticancer agent 49 shows antiproliferative activity with IC₅₀s of 5, 8, 10, 10, 12 nM for KU812, LAMA84-S, LAMA84-R, KBM5-WT, KBM5-T315I cells, respectively^[1].
Anticancer agent 49 shows growth inhibition with IC₅₀s of 22, 48, 24, 303, 147, 41, 34, 153, 61, 58 nM for U343G, U87MG, T98G, SK-N-BE, SK-N-BE(2)-C, HT29, HCT116, SW480, SW620, T24 cell, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Cell Viability Determination by MTT Colorimetric Assay

化学情報

CAS 番号 2395009-34-2
分子量 443.49
分子式 C₂₆H₂₅N₃O₄
SMILES

COC1=CC(C(C2=CN(C=C2C3=CC=C(C=C3)N)C4=CC=C(C=C4)N)=O)=CC(OC)=C1OC
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (271 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Puxeddu M, et al. Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies. Eur J Med Chem. 2020 Jan 1;185:111828. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ